John B. Bode - 13 May 2024 Form 4 Insider Report for ZEVRA THERAPEUTICS, INC. (ZVRA)

Reporting relationship: Director
Issuer ticker: ZVRA
Reported as of: 13 May 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 May 2024, 21:31:46 UTC
Prior SEC filing: 01 Dec 2023
Next SEC filing: 15 Jul 2024
Source filing: View source filing
Reporting owner signature: /s/ Timothy J. Sangiovanni, Attorney-in-Fact for John B. Bode

Key filing fact

John B. Bode filed Form 4 for ZEVRA THERAPEUTICS, INC. (ZVRA) on 15 May 2024.

Key facts

This page summarizes John B. Bode's Form 4 filing for ZEVRA THERAPEUTICS, INC. (ZVRA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 May 2024, 21:31.

Change

Previous filing in this sequence was filed on 01 Dec 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZVRA transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +39,200
Change %
Price: $0.000000
Shares after: 39,200
Date: 13 May 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 39,200
Exercise price: $4.89
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, May 13, 2024.

Footnote F2

This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's ninth amended and restated non-employee director compensation policy.

Footnote F3

One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.